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Conclusions of the WHO international meeting on prisons and health 
Lisbon 2017 
The World Health Organization (WHO) international meeting on prisons and health, held in 
Lisbon, Portugal, on 11–12 December 2017, brought together more than 100 experts in the 
field of prison and public health from 30 countries worldwide; besides the WHO Regional Office 
for Europe and WHO Headquarters several other international and European agencies were 
represented, including the European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA), the Council of Europe’s Pompidou Group, the European Centre for Disease 
Prevention and Control, the United Nations Office on Drugs and Crime, and the Ministry of 
Health and the Ministry of Justice of Portugal; support was provided by Public Health England 
(PHE),  the UK Collaborating Centre for the WHO Health in Prisons Programme (HIPP). 
The meeting participants propose the following conclusions for wider dissemination to all those 
who could improve the current position worldwide with respect to drugs and drug-related 
harms in prison, which continue to challenge prison systems and the wider community. 
The WHO international meeting on prisons and health contributes to sharing good practice 
internationally, maintaining and improving professional development and capacity in the prison 
health system; it also allows discussion of the challenges currently facing the prison setting with 
respect to public health and health service delivery and encourages debate on the scientific 
evidence that supports policy and intervention. 
The meeting’s conclusions aim to fully acknowledge the role of prisons as important settings to 
address health inequalities and to recognize the status of people in prison as a disadvantaged 
group in terms of health and well-being. These conclusions direct the attention of policy-
makers, professionals and prison administrators to the necessity, in terms of both public health 
and social well-being, of enhancing knowledge and understanding of effective interventions on 
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drugs and drug-related harms in prison (including tobacco- and alcohol-related health harms), 
and of ensuring that interventions to reduce drug use and drug-related health harms are 
evidence-based, particularly in a setting as sensitive as a prison, where people have been 
deprived of their liberty. Applicable also to people in youth detention settings, these 
conclusions recognize that – in order to achieve lasting improvements in the health of people 
who experience incarceration – treatment and prevention efforts in prison and youth detention 
settings must be sustained after these individuals return to the community. 
CONCLUSIONS OF THE WHO INTERNATIONAL MEETING ON PRISONS AND HEALTH 
Lisbon 2017 
People in prison have higher rates of drug use and injecting than the general population, and 
people with drug-related problems make up a significant proportion of people in prison. Among 
high-risk drug users in the community, many will have repeat experience of detention.1 The 
likelihood of having contracted an infectious disease is higher among high-risk drug users with a 
prison history than among those who have never been incarcerated, and the risk of overdose 
death in the immediate period after release from prison is high. Therefore: 
Taking note of the current facts and figures regarding drugs and drug-related harms in prisons 
worldwide and the high rate of post-release mortality, as presented to the meeting by 
acknowledged international experts, 
Based on the evidence and experience of recognized experts in addressing drugs in prisons and 
their related harms, such as HIV, viral hepatitis B and C, and tuberculosis (TB), as well as mental 
health problems, 
Justified by the available evidence on effective harm-reduction measures, encouraged by the 
proven beneficial results obtained from initiatives such as opioid substitution therapy in prison 
and overdose prevention before release in other countries in the world, 
Aware of the potential for prisons to contribute to global public health protection and hence to 
a reduction of health inequalities by allowing opportunities to intervene in a vulnerable and 
high disease-burdened population which would impact on wider community health outcomes, 
Understanding that effective prevention depends on early recognition of those at risk at all 
stages of the criminal justice system, 
Emphasizing the fact that drug treatment in prisons must not be isolated from health services 
available in the community, 
Recognizing the significantly higher level of tobacco-smoking behaviour among people in prison 
and the opportunity to support smoking cessation in prison settings, 
                                                          
1
 European Monitoring Centre for Drugs and Drug Addiction. Prisons and drugs in Europe: the problem and 
responses. Luxembourg: Publications Office of the European Union; 2012 (https://doi.org/10.2810/73390). 
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Considering the health and economic burden of alcohol-related violence and the potential of 
prison settings for the delivery of effective alcohol interventions to achieve better health and 
rehabilitation outcomes for prisoners, 
Acknowledging the standards set out in the United Nations Standard Minimum Rules for the 
Treatment of Prisoners (also known as the Nelson Mandela Rules), including Rule 24, on 
providing the same standards of health care in the prison setting as in the community and 
ensuring continuity between the two, and Rule 25, on paying particular attention to addressing 
health care needs that may hamper rehabilitation,2 
This meeting recognizes the need for consideration of the following measures, programmes 
and guidelines aimed to reduce drug use and its associated harms in prison and invites policy-
makers, health and justice professionals, and prison administrators to: 
1) Implement a “whole-of-government approach” to prison health care,3 ensuring that the 
health and social care needs of people in prisons are considered in all policies, taking 
account of the need for integration between prison health and wider public health and 
social care systems, and recognizing prisons as a setting in which to address health 
inequalities, improve health  and assure equitable access to health services and thereby 
reduce reoffending; 
2) Operate within a framework of equivalence of health care outcomes between prison 
and community based on need and the requirement for continuity of care between 
community and prison; 
3) Treat the person as a whole, including psychosocial support as well as effective 
pharmacological treatment, recognizing that drug dependence treatment should take 
account of wider health and social care issues; 
4) Ensure that service design is informed by research evidence and that service delivery is 
evaluated by audit and/or appropriate implementation data that take into account the 
prison setting and the transition into the community from custody, requiring 
multiagency partnership work and a systems leadership approach to health; 
5) Develop and agree minimum staffing levels (both health care and custodial staff) and 
skill mix; ensure appropriate training and professional development for all staff to 
assure improvements in service delivery, acknowledging the challenges of working in a 
prison setting and the opportunities for all staff to impact on rehabilitation and reducing 
recidivism; 
                                                          
2
 United Nations Standard Minimum Rules for the Treatment of Prisoners (the Nelson Mandela Rules). Resolution 
adopted by the General Assembly, 8 January 2016, A/RES/70/175 (https://cdn.penalreform.org/wp-
content/uploads/1957/06/ENG.pdf). 
3
 Good governance for prison health in the 21st century. Copenhagen: WHO Regional Office for Europe; 2013 
(http://www.euro.who.int/__data/assets/pdf_file/0017/231506/Good-governance-for-prison-health-in-the-21st-
century.pdf). 
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6) Encourage use of the United Nations comprehensive package of services to address HIV, 
TB, and viral hepatitis B and C;4 and undertake prison reform measures to improve living 
and working conditions, and broader criminal justice reforms to develop, adopt and 
implement alternatives to conviction or punishment for drug related non-violent crime 
and to reduce the excessive use of (pre-trial) detention. 
 
                                                          
4
 European Centre for Disease Prevention and Control and the European Monitoring Centre for Drugs and Drug 
Addiction. Systematic review on active case finding of communicable diseases in prison settings. Stockholm: 
ECDC; 2017 (https://ecdc.europa.eu/sites/portal/files/documents/Systematic-review-on-communicable-diseases-
in-prison-settings-final-report.pdf). 
